CollPlant Biotechnologies: Q1 Earnings Insights
Portfolio Pulse from Benzinga Insights
CollPlant Biotechnologies (NASDAQ:CLGN) reported Q1 earnings with in-line EPS of $-0.29 and revenue up $367 thousand from the same period last year. Last quarter, the company missed EPS by $0.04, followed by a 0.0% increase in share price the next day.
May 24, 2023 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
CollPlant Biotechnologies reported Q1 earnings with in-line EPS and increased revenue. Last quarter, a missed EPS resulted in a 0.0% share price increase.
CollPlant Biotechnologies reported in-line EPS and increased revenue, which is a neutral signal for investors. Last quarter, the company missed EPS, but it did not have a significant impact on the share price. Therefore, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100